BRCA1 germline pathogenic in mCRPC: olaparib improves rPFS and OS post-NHA (PROfound Coho...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRCA1-GERMLINE-PROSTATE |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PROSTATE |
| Sources | SRC-CIVIC SRC-EAU-PROSTATE-2024 SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Actionability Facts
| Biomarker | BIO-BRCA1-BRCA2-GERMLINE |
|---|---|
| Variant | BRCA1 germline pathogenic |
| Disease | DIS-PROSTATE |
| ESCAT tier | IA |
| Recommended combinations | olaparib monotherapy (post-NHA), olaparib + abiraterone + prednisone (1L), niraparib + abiraterone + prednisone (1L), talazoparib + enzalutamide (1L), rucaparib monotherapy (post-NHA + taxane) |
| Evidence summary | BRCA1 germline pathogenic in mCRPC: olaparib improves rPFS and OS post-NHA (PROfound Cohort A, de Bono 2020); rucaparib (TRITON2/3) and niraparib (MAGNITUDE BRCA subset) also approved. 1L olaparib + abiraterone (PROpel) and niraparib + abiraterone (MAGNITUDE) extend rPFS in HRR-positive mCRPC. ESCAT IA / OncoKB Level 1. |
Notes
Germline mandates cascade testing (Lynch-like family-line implications, plus elevated breast/ovarian risk in carrier relatives). NCCN strongly recommends germline testing in all metastatic prostate cancer.
Used By
No reverse references found in the YAML corpus.